Zacks Investment Research upgraded shares of Senestech, Inc. (NASDAQ:SNES) from a sell rating to a hold rating in a research note issued to investors on Friday morning.
According to Zacks, “SenesTech, Inc. developed technology for managing animal pest populations through fertility control as opposed to a lethal approach. The Company’s fertility control product candidate, ContraPest(R), will be marketed for use initially in controlling rat infestations. SenesTech, Inc. is based in Flagstaff, Arizona. “
Separately, Roth Capital set a $14.00 target price on Senestech and gave the stock a buy rating in a research note on Saturday, May 13th.
Senestech (SNES) opened at 2.16 on Friday. The company’s market capitalization is $22.30 million. The stock’s 50 day moving average price is $2.76 and its 200-day moving average price is $5.95. Senestech has a one year low of $2.03 and a one year high of $10.69.
Senestech (NASDAQ:SNES) last announced its earnings results on Thursday, August 10th. The company reported ($0.35) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by $0.07. The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.10 million. Equities analysts forecast that Senestech will post ($1.30) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This story was first reported by Markets Daily and is the property of of Markets Daily. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.themarketsdaily.com/2017/09/11/senestech-inc-snes-upgraded-at-zacks-investment-research.html.
In other Senestech news, Director Grover T. Wickersham bought 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 25th. The shares were purchased at an average cost of $2.85 per share, for a total transaction of $42,750.00. Following the purchase, the director now directly owns 238,600 shares in the company, valued at $680,010. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Andrew Altman bought 20,000 shares of the company’s stock in a transaction that occurred on Friday, August 18th. The shares were acquired at an average price of $2.77 per share, for a total transaction of $55,400.00. Following the completion of the purchase, the chief operating officer now owns 2,600 shares in the company, valued at $7,202. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 54,100 shares of company stock worth $155,730 and have sold 13,411 shares worth $35,333. 27.40% of the stock is owned by insiders.
An institutional investor recently bought a new position in Senestech stock. White Pine Capital LLC bought a new position in shares of Senestech, Inc. (NASDAQ:SNES) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 19,250 shares of the company’s stock, valued at approximately $110,000. White Pine Capital LLC owned about 0.19% of Senestech at the end of the most recent reporting period. 15.34% of the stock is currently owned by institutional investors.
Senestech Company Profile
SenesTech, Inc is a United States-based biotechnology platform and research company. The Company is engaged in developing a technology for managing animal populations by fertility control. It offers ContraPest, a fertility control product candidate. ContraPest’s technology and approach targets the reproductive capabilities of both sexes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Senestech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senestech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.